Psoriasis and Psoriatic Arthritis Drugs Crisscross Categories, but Derm and Rheum Docs Split on Preferences
As drugs in psoriasis and psoriatic arthritis therapy areas nab new indications that crisscross the two categories, dermatologists and rheumatologists are assessing their options. The twist? Emerging opinions between the two doctor groups are exactly the opposite, according to Spherix Global Insights research analysis.
‘Risk Averse’ Rheumatologists Report Declining JAK Use, Increased Reliance on Abatacept
The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data. The market analysis firm Spherix Global Insights surveyed 102 rheumatologists through the first quarter of 2022 and found that rheumatologists are increasingly opting for abatacept (Orencia, Bristol […]
Spherix Global Insights Announces Exhibition and Releases the Title of Their Abstract to be Presented at the 2022 ARVO Annual Meeting
Recent survey data reveals changes afoot in the neovascular (wet) age-related macular degeneration market EXTON, Pa., March 2, 2022 /PRNewswire/ — Spherix Global Insights, an independent market intelligence firm, recently collected feedback from 103 US ophthalmologists on the neovascular age-related macular degeneration (nAMD) treatment landscape. Insights from the RealTime Dynamix™ report revealed that market leader, […]
Spherix Uncovers Key Differences in the Management of Chronic Kidney Disease Patients in Europe Versus the U.S.
New analysis of European CKD non-dialysis patient chart data reveals notable differences in nephrologists’ use of renal therapies, including SGLT2 inhibitors EXTON, Pa., / April 25, 2022 / PRNewswire – The approval of several renal pipeline products in the European market has granted nephrologists new options through which they can manage their patients with chronic […]
C. Diff — A Promising Pipeline Addressing Unmet Need
Spherix’s Gastroenterology Franchise Head, Eric John, reflects on his time researching clostridioides difficile (C. diff) and explains the current state of the market, as well as upcoming pipeline agents. Throughout my time in the gastroenterology field, the CDI market has continued to evolve in order to provide options with increased efficacy for those who suffer […]
Bristol Myers Squibb’s Aging Orencia Finds New Life with Rheumatologists as They Shun Newer JAK Drugs from Pfizer, AbbVie: Report
Bristol Myers Squibb is the surprise winner in an emerging rheumatoid arthritis (RA) market dynamic as doctors eschew new JAK inhibitors amid safety concerns. That’s the analysis of a new first-quarter 2022 report by Spherix, which surveyed 102 U.S. rheumatologists on their recent prescribing habits. The survey found a “potential paradigm shift” away from JAK […]
New Spherix Research Suggests Rheumatologists Are Gravitating Towards BMS’ Orencia for the Treatment of Rheumatoid Arthritis as JAK Inhibitor Use Declines
Potential paradigm shifts in the post-TNF and later-line setting leave ample opportunity for alternate mechanism agents EXTON, Pa., April 6, 2022 /PRNewswire/ — The US rheumatoid arthritis (RA) biologic and small molecule market has remained relatively stagnant over the past few years, with little change in prescribing habits and a lack of new commercial developments. However, […]
Novartis’ Kesimpta is Poised for Strong Growth in the European Multiple Sclerosis Market, Spherix Global Insights Reports
Favorable reimbursement decisions for Ponvory may accelerate uptake for the Janssen brand EXTON, Pa., April 5, 2022 / PRNewswire / — Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the multiple sclerosis (MS) market in Europe through their RealTime Dynamix™: Multiple Sclerosis (EU) service since 2017. […]
Hidradenitis Suppurativa — The Future of Patient Management
![](https://www.spherixglobalinsights.com/wp-content/uploads/2020/12/spherix-global-insights-default-og.png)
Spherix’s Dermatology Franchise Head, Gianna Melendez, discusses insights she’s uncovered from her work in the hidradenitis suppurativa (HS) market and looks to the future of disease management. What is hidradenitis suppurativa? Hidradenitis suppurativa (HS), or acne inversa, is a chronic inflammatory condition that causes painful and recurrent abscesses. Eventually, the illness progresses to the […]
IgA Nephropathy Market Shakes Up with Tarpeyo (Calliditas) Launch and Surge in Physician Prescribing of SGLT2 Inhibitors, Spherix Reports
Insights garnered from the newest launch report for Tarpeyo and recently published IgA nephropathy patient chart audit reveal shifting tides in the treatment landscape EXTON, Pa., March 28, 2021 /PRNewswire/ — IgA nephropathy (IgAN) is generally recognized as the most common glomerular nephritis disease globally, impacting many patients and often resulting in ESRD and dialysis […]